Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Issue 12 (23rd December 2022)

• Record Type: Journal Article
• Authors: Lodi, Sara; Klein, Marina; Rauch, Andri; Epstein, Rachel; Wittkop, Linda; Logan, Roger; Rentsch, Christopher T.; Justice, Amy C.; Touloumi, Giota; Berenguer, Juan; Jarrin, Inma; Egger, Matthias; Puoti, Massimo; D'Arminio Monforte, Antonella; Gill, John; Salmon Ceron, Dominique; van Sighem, Ard; Linas, Benjamin; van der Valk, Marc; Hernán, Miguel A.
• Is Part Of: Journal of the International AIDS Society. Volume 25:Issue 12(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-23
• Subjects: HIV and HCV co‐infection -- direct antiviral agents -- sustained virological response -- causal inference -- parametric g‐formula -- missing data; AIDS (Disease) -- Periodicals; HIV infections -- Periodicals; 616.9792005
• DOI: 10.1002/jia2.26048
• Languages: English
• ISSNs: 1758-2652

Abstract

Abstract: Introduction: Randomized trials and observational studies have consistently reported rates of sustained virological response (SVR), equivalent to hepatitis C virus (HCV) cure, as high as 95% following treatment with direct‐acting antiviral (DAA) treatment in individuals with HIV and HCV co‐infection. However, large studies assessing whether SVR rates differ according to demographic and clinical strata are lacking. Additionally, the SVR rates reported in the literature were typically computed in non‐random samples of individuals with available post‐DAA HCV‐RNA measures. Here, we aimed to estimate the probability of SVR after DAA treatment initiation in persons with HIV and HCV co‐infection overall and by demographic and clinical characteristics with and without adjustment for missing HCV‐RNA testing. Methods: We included adults with HIV‐HCV co‐infection who received DAA treatment between 2014 and 2020 in HepCAUSAL, an international collaboration of cohorts from Europe and North America. We estimated the proportions of DAA recipients who had documented SVR (defined as an undetectable HCV‐RNA at least 12 weeks after the end of DAA treatment) overall and by strata defined by age, sex, presence of cirrhosis, calendar period, mode of HIV acquisition, CD4 cell count and HCV genotype at DAA treatment. We then compared these rates with those obtained using the parametric g‐formula to impute SVR status for individuals with no SVR assessment. Results and Discussion: A total of 4527 individuals who initiated DAA treatment (88% males, median [IQR] age 56 [50, 62] years) were included. Of the total of 642 (14%) individuals had no HCV‐RNA test on or after 12 weeks after the end of treatment. The overall observed and g‐formula imputed SVR rates were 93% (95% CI 93, 94) and 94% (95% CI 92, 95), respectively. SVR estimates were similarly high across all strata. A substantial proportion of individuals who received DAA treatment were never assessed for SVR post‐DAA and strategies for more systematic routine HCV‐RNA testing should be considered. Conclusions: Our estimates with and without adjustment for missing HCV‐RNA testing indicate SVR rates of approximately 95%, like those reported in clinical trials.